A Single-Arm Phase Ic Clinical Study of XKH001 Injection in Patients With Allergic Asthma After Multiple Doses

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 26, 2023

Primary Completion Date

October 10, 2024

Study Completion Date

December 20, 2024

Conditions
Asthma Patients
Interventions
DRUG

XKH001 Injection

Dosage: 600 mg Q4W (D1, D29 and D57) Method of administration: the drug will be administered by SC injection in an area 3 cm away from and within 5 cm around the umbilicus of the abdomen. Sites with skin damage, inflammation, ulceration, rash and scar should be avoided. Subjects should be closely observed for reactions within 4 h after dosing.

Trial Locations (1)

310000

The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Zhejiang Kanova Biopharmaceutical Co., LTD

INDUSTRY

NCT07070297 - A Single-Arm Phase Ic Clinical Study of XKH001 Injection in Patients With Allergic Asthma After Multiple Doses | Biotech Hunter | Biotech Hunter